A TWiV duo reviews how SARS-CoV-2 attacks the olfactory mucosa but spares the olfactory bulb, vaccination with BNT162b2 induces virus-specific stem cell memory T cells, and development of an oral protease inhibitor for the treatment of COVID-19.
In COVID-19 clinical update #88, Dr. Griffin covers vaccine protection among US veterans, absence of long COVID in vaccinated who are infected, single dose of REGEN-COV monoclonal antibody cocktail provides long term protection, and Pfizer protease inhibitor Paxlovid is 89% effective in preventing hospitalization or death.
Greg Zuckerman joins TWiV to discuss his book that explores the race to produce COVID-19 vaccines, with insights into the companies, scientists, and executives involved and the rivalries, ambitions, ego, and a desire to save the world.
In COVID-19 clinical update #87, Dr. Griffin reviews PCR cycle threshold and RNA copy number, rapid antigen tests, hospitalization rate after infection or vaccination, allergies and vaccination, community transmission and viral RNA load, early treatment with sotrovimab, meta-analysis of tocilizumab treatment, antibiotic overuse, and guidelines on the use of anticoagulation for thromboprophylaxis.
In this special live-streamed episode of TWiV, Dr. Daniel Griffin fields questions on SARS-CoV-2 and COVID-19 from listeners.
TWiV explores the properties of the spike glycoproteins of an influenza B virus discovered in the Wuhan spiny eel, and protection against SARS-CoV-2 infection one year after mRNA-1273 vaccination of nonhuman primates.
In COVID-19 clinical update #86, Dr. Griffin discusses virologic features of infection in children, antibody tests should not be used to asses level of protection, test-to-stay programs in schools, FDA authorizes Moderna boosters, results of TOGETHER trial for fluvoxamine, statins and 28 day mortality, and cognitive function in patients.
In COVID-19 clinical update #85, Dr. Griffin reviews cases and deaths by vaccination status, mRNA vaccine effectiveness in 12-18 year olds, standard and extended dosing of mRNA vaccines, immune responses after vaccination, Moderna booster dose approved, giving monoclonals at home, no benefit from colchicine, and IFN does not help remdesivir.
TWiV explains how remdesivir inhibits the SARS-CoV-2 RNA polymerase: the drug is incorporated into the growing RNA chain and causes synthesis to stall when the drug clashes with an amino acid in the active site.
The TWiVers review phase 3 efficacy and safety results for the Novavax COVID-19 vaccine, effects on the neonatal immune system caused by maternal infection with SARS-CoV-2, and NHC, the metabolite of molnupiravir, causes mutations in cellular DNA.
The Hosts of TWiV
Vincent Racaniello, Ph.D.
Brianne Barker, Ph.D.
Rich Condit, Ph.D.
Alan Dove, Ph.D.
Daniel Griffin, M.D.,
Ph.D., CTropMed CTH
Angela Mingarelli, DVM
Jolene Ramsey, Ph.D.
Kathy Spindler, Ph.D.